RxDoctor Payments Data

Hussam Hamdalla, MD

Interventional Cardiology · Lexington, KYNPI 1871527804

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (46.8%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 56 manufacturers reported payments, led by Shockwave Medical, Inc at 43.3% of the total. 2025 is the largest year on record at $7,582, 2.1 times the $3,657 reported in 2019.

$24,276in general payments, 2019–2025

Across 450 payments — averaging $53.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$11K
  • Medtronic$3K
  • Terumo Medical Corporation$2K
  • Novartis$974
  • Boston Scientific$862
  • Endologix LLC$757
  • plus $6K from 50 others
$17,046in research payments, 2019–2025

Across 4 payments — averaging $4261.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$17K

What the payments were for

  • Consulting fees$5,50023%
  • Speaking & faculty fees$4,95020%
  • Travel & lodging$2,46910%
  • Food & beverage$11,35047%
  • Education$70%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,276 in reported general payments places this provider in the 80th percentile of 129 interventional cardiology providers in Kentucky.

See all interventional cardiology providers in Kentucky

Medicare billing

Part B allowed, 2024
$132,024
Medicare patients
797
Services billed
1,869

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban55$73,163
EntrestoSacubitril/Valsartan53$52,294
XareltoRivaroxaban34$33,490
JardianceEmpagliflozin26$30,507
FarxigaDapagliflozin Propanediol35$23,907
Repatha SureclickEvolocumab29$20,859
BrilintaTicagrelor12$8,632
Ranolazine ErRanolazine50$6,008
Metoprolol Succinate170$1,725
Diltiazem 12hr ErDiltiazem Hcl11$1,074
ClopidogrelClopidogrel Bisulfate139$810
Atorvastatin Calcium67$766
Bisoprolol Fumarate28$758
Losartan Potassium85$691
Carvedilol119$641

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$684$73,16355 claims
NovartisEntresto$974$52,29453 claims
Johnson & JohnsonXarelto$143$33,49034 claims
AstraZenecaFarxiga, Brilinta$195$32,53847 claims
Boehringer IngelheimJardiance$19$30,50726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 129 interventional cardiology providers in Kentucky.

Other interventional cardiology in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →